Asia Pacific Vaccines Market

The Asia Pacific vaccines market (excluding COVID-19) is projected to reach USD 14.57 billion by 2030, from USD 9.46 billion in 2025, with a CAGR of 9.0%. This growth is attributed to several factors, such as ongoing advancements in vaccine development technologies and rising healthcare expenditure.

Key market players include Serum Institute of India (India), Pfizer Inc. (US), Merck & Co., Inc. (US), GSK (UK), Bharat Biotech (India), Panacea Biotec (India), Biological E Limited (India), and Mitsubishi Tanabe Pharma Corporation (Japan). These companies are expanding beyond traditional vaccine production into high-throughput, automated platforms that include adjuvant optimization, viral inactivation processes, subunit protein expression, and specialized cold chain-compatible reagents for multi-dose vial workflows. By increasing fill-finish capacity and using modular bioreactor systems, they aim to improve regional self-reliance, supporting vaccine programs from preclinical strain isolation and Phase I-II trials in local populations to national deployment for outbreak response and herd immunity.

To know about the assumptions considered for the study download the pdf brochure

Serum Institute of India (India)

Serum Institute of India is a leading vaccine manufacturer in Asia Pacific, leveraging high-volume fermentation platforms, automated single-use bioreactor systems, and strong lyophilization processes to produce scalable vaccines like measles-rubella and new dengue candidates. By expanding facilities in Pune and collaborating with global technology partners, the company positions itself as a comprehensive partner for governments and biopharma companies seeking affordable, large-volume supplies to support national immunization campaigns across India and Africa.

Pfizer Inc. (US)

Pfizer Inc. leads the Asia Pacific vaccines market with mRNA synthesis platforms, continuous manufacturing lines, and AI-integrated process analytics, enabling quick production of influenza boosters and RSV vaccines tailored for aging APAC populations. With new CDMOs in Singapore and investments in regional cold chain logistics, the company has become a key partner for public health agencies and hospitals needing agile, high-efficacy vaccine supplies to fight seasonal and emerging threats.

Merck & Co., Inc. (US)

Merck & Co., Inc. is among the top vaccine players in Asia Pacific, integrating viral vector platforms, automated fill-finish systems, and advanced conjugation technologies to deliver potent HPV and pneumococcal vaccines at scale. Through facility expansions in Japan and strategic alliances with local manufacturers, the company establishes itself as a comprehensive partner for clinical developers and health ministries pursuing sustained immunization coverage in urban and rural settings.

Market Ranking

Leading Asia Pacific vaccine companies are moving beyond traditional production toward high-throughput, automated platforms that include adjuvant optimization, viral inactivation, subunit protein expression, and specialized reagents for multi-dose vials and regional pathogen workflows. Serum Institute of India uses fermentation bioreactors and Pune expansions to enable scalable measles-dengue supply, while Pfizer utilizes mRNA lines with Singapore CDMOs for a quick influenza-RSV response. Merck combines viral vectors and partnerships in Japan for HPV-pneumococcal scale-up. GSK improves adjuvant systems through Hyderabad upgrades for shingles innovation, and Bharat Biotech streamlines Algel-IMDG platforms for TB boosters. These ecosystems cover everything from strain isolation to national rollout, positioning themselves as comprehensive partners for precise immunization across various settings.

Related Reports:

Asia Pacific Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com